Retreatment of hepatitis C non-responsive to Interferon : a placebo-controlled randomized trial of Ribavirin in monotherapy versus combination therapy with Ribavirin and Interferon in patients in the BeneluxRetreatment of hepatitis C non-responsive to Interferon : a placebo-controlled randomized trial of Ribavirin in monotherapy versus combination therapy with Ribavirin and Interferon in patients in the Benelux
Faculty of Medicine and Health Sciences
Research group
Laboratory Experimental Medicine and Pediatrics (LEMP)
Publication type
Human medicine
Source (journal)
BMC gastroenterology. - London
3(2003):24, 9 p.
Article Reference
E-only publicatie
Target language
English (eng)
Full text (Publishers DOI)
University of Antwerp
Background: Evidence based medicine depends on unbiased selection of completed randomized controlled trials. For completeness it is important to publish all trials. This report describes the first large randomised controlled trial where combination therapy was compared to placebo therapy and to ribavirin monotherapy, which has not been published untill now. Methods: One hundred and twenty one patients with chronic hepatitis C and elevated transaminases who did not respond to previous treatment with standard interferon monotherapy, were included from 16 centers in Belgium, the Netherlands and Luxembourg between 1992 and 1996. Patient poor-response characteristics were: genotype 1 (69%), HCV RNA above 2 x 106 copies/ml (55%) and cirrhosis (38%). Patients were randomized to 6 months combination therapy with interferon alpha-2b ( 3 MU tiw) and ribavirin ( 1000 - 1200 mg / day), 6 months ribavirin monotherapy ( 1000 - 1200 mg / day) or 6 months ribavirin placebo. The study was double blinded for the ribavirin / placebo component. One patient did not fit the entry criteria, and 3 did not start. All 117 patients who received at least one dose of treatment were included in the intention to treat analysis. Results: At the end of treatment, HCV RNA was undetectable in 35% of patients on combination therapy and in none of the patients treated with ribavirin monotherapy or placebo. The sustained virological response rate at 6 months after therapy was 15% for patients treated with interferon and ribavirin. During the 6 months treatment period 13% of patients on interferon ribavirin combination therapy, 13% of patients on ribavirin monotherapy and 11% of patients on placebo withdrew due to side effects or noncompliance. At 24 weeks of treatment the mean Hb level was 85% of the baseline value, which means a mean decrease from 9.1 mmol/l to 7.8 mmol/l. The Hb levels at the end of treatment were not significantly different from patients treated with ribavirin monotherapy ( p = 0.76). End of treatment WBC was significantly lower in patients treated with combination therapy, compared to ribavirin ( p < 0.01) as well as for patients treated with ribavirin monotherapy compared to placebo ( p < 0.01). Discussion: This belated report on the only placebo controlled study of interferon ribavirin combination therapy in non responders to standard doses of interferon monotherapy documents the effectiveness, be it limited, of this approach as well as the dynamics of the effects on blood counts.
Full text (open access)